TPC Publishes Landmark Study in Nature Medicine on Multi-Omics Tumor Profiling for Melanoma

The Tumor Profiler Center is proud to announce the publication of groundbreaking research in Nature Medicine demonstrating the feasibility and clinical impact of multi-omics tumor profiling for guiding melanoma treatment. Published on May 27, 2025, this landmark study provides compelling real-world evidence for personalized cancer care.

The article "Feasibility of multiomics tumor profiling for guiding treatment of melanoma" details the power of multi-omics and functional profiling to guide treatment decisions in advanced melanoma. The study was based on results from the TuPro trial, a prospective, multicenter observational trial in which samples from patients with melanoma were analyzed using cutting-edge profiling technologies to generate insights into the unique molecular characteristics for each patient.

These insights were then used by a molecular tumor board to guide clinical recommendations. This study highlights that in 75% of cases, TuPro-derived insights were deemed clinically useful. Patients receiving highly individualized, data-informed treatments beyond the standard of care achieved a 38% response rate. This and other findings from the study showcase the clinical value of precision oncology.

The TuPro Study Approach

The TuPro trial employed a comprehensive multi-omics approach, integrating multiple cutting-edge technologies to analyze tumor samples. This included next-generation sequencing (NGS), digital pathology (DigiPath), cytometry by time of flight (CyTOF), pharmacoscopy, single-cell RNA sequencing (scRNA), single-cell DNA sequencing (scDNA), 4i drug response profiling (4iDRP), imaging mass cytometry (IMC), and proteotyping.

Within just four weeks from sample acquisition, the integrated data analysis generated comprehensive biomarker results and molecular research reports. These were delivered to a pre-tumor board meeting, leading to treatment recommendations and ultimately supporting molecular tumor board (MTB) decisions on personalized therapy approaches.

Clinical Impact and Significance

The study provides compelling real-world evidence for the feasibility and impact of omics-based, integrative tumor profiling in oncology care, and marks a significant step toward making truly personalized cancer care a reality. The high rate of clinically useful insights and improved response rates demonstrate the tangible benefits of precision oncology approaches for patients with advanced melanoma.

This publication represents years of collaborative work by the TPC consortium, bringing together expertise from basic scientists and clinicians at ETH Zürich, University of Zurich (UZH), University Hospital Zurich (USZ), and University Hospital Basel (USB). The success of the TuPro trial validates the TPC's mission to employ cutting-edge, integrated, multi-omics tumor profiling techniques to support clinical decision-making in precision oncology.